PROGNOSTIC FACTORS OF RELAPSE IN THE SURGICAL TREATMENT OF DESMOID FIBROIDS OF THE TRUNK AND EXTREMITIES
https://doi.org/10.17709/2409-2231-2019-6-1-2
Abstract
Purpose of the study. Evaluation of the results of surgical treatment of desmoid fibroids (DF) using reconstructive plastic surgery and determination of possible prognostic factors of relapses.
Patients and methods. The results of surgical treatment of 40 patients with desmoid fibroids of extra abdominal localization were analyzed. In 45% of patients, the tumor was located in soft tissues of the shoulder girdle and upper limb, in 35% — on the trunk, in 20% — in soft tissues of the lower limb and in 7% of patients on the neck. The tumor size varied from 2 to 20 cm, the median was 8 ± 4.38 cm. Surgical treatment for newly diagnosed DF was performed in 22 (55%) patients, and for recurrent tumors — in 18 (45%) patients.
Results. According to the planned histological study, negative resection boundaries were established in 24/40 patients (63%). In the remaining 16 cases (37%) positive resection margins were obtained: R1 in 14 patients and R2 in 2 patients. Adjuvant treatment is recommended for 14 patients with resection R1/R2. The duration of follow — up after treatment ranged from 6 to 107 months, median‑16.5 months. During follow-up, relapses were diagnosed in 14 patients (35%). No deaths have been reported.
Conclusion. Surgical treatment of DF of extraabdominal localization is accompanied by a sufficiently high frequency of relapses. According to the results of the study, an unfavorable factor in the development of relapses is the location of the tumor in soft tissues of the shoulder girdle and upper limb.
About the Authors
A. V. Yadrina
P.Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre
Russian Federation
Russian Federation
oncologist in department of oncoortopedical surgery
3, 2nd Botkinskiy proezd, Moscow, 125284, Russian Federation
V. Yu. Karpenko
P.Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre
Russian Federation
Russian Federation
MD, PhD, DSc, head of oncoortopediacl surgery department
3, 2nd Botkinskiy proezd, Moscow, 125284, Russian Federation
O. V. Novikova
P.Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre
Russian Federation
Russian Federation
MD, PhD, DSc, Leading Researcher, Department of Reproductive and Urinary Organ Tumors
3, 2nd Botkinskiy proezd, Moscow, 125284, Russian Federation
N. M. Bychkova
P.Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre
Russian Federation
Russian Federation
MD, PhD, head of day hospital Department of radiation therapy
3, 2nd Botkinskiy proezd, Moscow, 125284, Russian Federation
V. A. Derzhavin
P.Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre
Russian Federation
Russian Federation
MD, PhD, senior researcher of the Department of Oncology
3, 2nd Botkinskiy proezd, Moscow, 125284, Russian Federation
A. V. Bucharov
P.Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre
Russian Federation
Russian Federation
MD, PhD, senior researcher of the Department of Oncology
3, 2nd Botkinskiy proezd, Moscow, 125284, Russian Federation
References
1. Salas S, Dufresne A, Bui B, Blay JY, Terrier P, Ranchere-Vince D, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: A wait-and-see policy according to tumor presentation. J Clin Oncol. 2011 Sep 10;29 (26):3553–8. DOI: 10.1200/JCO.2010.33.5489
2. de Camargo VP, Keohan ML, D’Adamo DR, Antonescu CR, Brennan MF, Singer S, et al. Clinical outcomes of systemic therapy for patients with deep bromatosis (desmoid tumor). Cancer. 2010 May 1;116 (9):2258–65. DOI: 10.1002/cncr.25089.
3. Dômont J, Salas S, Lacroix L, Brouste V, Saulnier P, Terrier P, et al. High frequency of beta-catenin heterozygous mutations in extraabdominal fibromatosis. Br J Cancer. 2010 Mar 16;102 (6):1032–6. DOI: 10.1038/sj.bjc.6605557
4. Mullen JT, DeLaney TF, Rosenberg AE, Le L, Iafrate AJ, Ko¬bayashi W, et al. β-Catenin mutation status and outcomes in sporadic desmoid tumors. Oncologist. 2013;18 (9):1043–9. DOI: 10.1634/theoncologist.2012–0449
5. Lazar AJ, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, MayordomoAranda E, et al. Specific mutations in the betacatenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008 Nov;173 (5):1518–27. DOI: 10.2353/ajpath.2008.080475.
6. Spear MA, Jennings LC, Mankin HJ, Spiro IJ, Spring eld DS, Gebhardt MC, et al. Individualizing management of aggressive bromatoses. Int J Radiat Oncol Biol Phys. 1998 Feb 1;40 (3):637–45.
7. Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: Prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999 Jan;17 (1):158–67. DOI: 10.1200/JCO.1999.17.1.158
8. Merchant NB, Lewis JJ, Woodruff JM, Leung DH, Brennan MF. Extremity and trunk desmoid tumors: A multifac- torial analysis of outcome. Cancer. 1999 Nov 15;86 (10):2045–52.
9. Lewis JJ, Boland PJ, Leung DH, Woodruff JM, Brennan MF. The enigma of desmoid tumors. Ann Surg. 1999 Jun;229 (6):866–72; discussion 872–3.
10. Gronchi A, Casali PG, Mariani L, Lo Vullo S, Colecchia M, Lozza L, et al. Quality of surgery and outcome in extra-abdominal aggressive bromatosis: A series of patients surgically treated at a single institution. J Clin Oncol. 2003 Apr 1;21 (7):1390–7. DOI: 10.1200/JCO.2003.05.150
11. Crago AM, Denton B, Salas S, Dufresne A, Mezhir JJ, Hameed M, et al. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg. 2013 Aug;258 (2):347– 53. DOI: 10.1097/SLA.0b013e31828c8a30.
12. Colombo C, Miceli R, Le Péchoux C, Palassini E, Honoré C, Stacchiotti S, et al. Sporadic extra abdominal wall desmoid-type fibromatosis: Surgical resection can be safely limited to a minority of patients. Eur J Cancer. 2015 Jan;51 (2):186–92. DOI: 10.1016/j.ejca.2014.11.019
13. Bonvalot S, Ternès N, Fiore M, Bitsakou G, Colombo C, Honoré C, et al. Spontaneous regression of primary abdominal wall desmoid tumors: More common than previously thought. Ann Surg Oncol. 2013 Dec;20 (13):4096–102. DOI: 10.1245/s10434–013–3197 x.
14. Briand S, Barbier O, Biau D, Bertrand-Vasseur A, Larousserie F, Anract P, Gouin F. Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. J Bone Joint Surg Am. 2014 Apr 16;96 (8): e69. DOI: 10.2106/JBJS.N.00020.
15. Eastley N, Aujla R, Silk R, Richards CJ, McCulloch TA, Esler CP, Ashford RU. Extra-abdominal desmoid fibromatosis-a sarcoma unit review of practice, long term recurrence rates and survival. Eur J Surg Oncol. 2014 Sep;40 (9):1125–30. DOI: 10.1016/j.ejso.2014.02.226.
16. Shin SH, Ko KR, Cho SK, Choi YL, Seo SW. Surgical outcome of desmoid tumors: Adjuvant radiotherapy delayed the recurrence, but did not affect long-term outcomes. J Surg Oncol. 2013 Jul;108 (1):28–33. DOI: 10.1002/jso.23343.
17. Lev D, Kotilingam D, Wei C, Ballo MT, Zagars GK, Pisters PW, et al. Optimizing treatment of desmoid tumors. J Clin Oncol. 2007 May 1;25 (13):1785–91. DOI: 10.1200/JCO.2006.10.5015
18. Dar’yalova SL, Boiko LV, Bychkova NM. Desmoidnye fibromy: sovremennoe sostoyanie problemy. Rossiiskii onkologicheskii zhurnal (Russian Journal of Oncology). 2008;3:54–5. (In Russian).
19. Bychkova NM, Daryalova SL, Boiko AV, Novikova OV. Desmoid fibromas: the specific features of their clinical course and the results of treatment in male patients. Rossiiskii onkologicheskii zhurnal (Russian Journal of Oncology). 2009;2:23– 31. (In Russian).
20. Daryalova SL, Frank GA, Karpenko VU, Ilushin AL, Bukharov AV, Derzhavin VA, et al. Aggressive fibromatosis — surgical approach as a part of combined treatment. Bone and soft tissue sarcomas and tumors of the skin. 2010;4:34–9. (In Russian).
21. Sri-Ram K, Haddo O, Dannawi Z, Tirabosco R, Cannon SR, Briggs TW, Sinisi M. The outcome of extra-abdominal fibromatosis treated at a tertiary referral center. Eur J Surg Oncol. 2012 Aug;38 (8):700–5. DOI: 10.1016/j.ejso.2012.03.005.
22. Huang K, Wang CM, Chen JG, Du CY, Zhou Y, Shi YQ, Fu H. Prognostic factors influencing event-free survival and treatments in desmoid-type fibromatosis: analysis from a large institution. Am J Surg. 2014 Jun;207 (6):847–54. DOI: 10.1016/j.amjsurg.2013.08.007
23. Zeng W, Zhou ZX, Liang JW, Hou HR, Wang Z, Zhou HT, et al. Prognostic factors for desmoid tumor: a surgical series of 233 patients at a single institution. Tumour Biol. 2014 Aug;35 (8):7513– 21. DOI: 10.1007/s13277–014–2002–1
24. Mullen JT, Delaney TF, Kobayashi WK, Szymonifka J, Yeap BY, Chen YL, et al. Desmoid Tumor: Analysis of Prognostic Factors and Outcomes in a Surgical Series. Ann Surg Oncol. 2012 Dec;19 (13):4028–35. DOI: 10.1245/s10434–012–2638–2
25. Janssen ML, van Broekhoven DL, Cates JM, Bramer WM, Nuyttens JJ, Gronchi A, et al. Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis. Br J Surg. 2017 Mar;104 (4):347–357. DOI: 10.1002/bjs.10477
26. Woltsche N, Gilg MM, Fraissler L, Liegl-Atzwanger B, Beham A, Lackner H, et al. Is wide resection obsolete for desmoid tumors in children and adolescents? Evaluation of histological margins, immunohistochemical markers, and review of literature. Pediatr Hematol Oncol. 2015 Feb;32 (1):60–9. DOI: 10.3109/08880018.2014.956905
27. Soto-Miranda MA, Sandoval JA, Rao B, Neel M, Krasin M, Spunt S, et al. Surgical treatment of pediatric desmoid tumors. A 12 year, single-center experience. Ann Surg Oncol. 2013 Oct;20 (11):3384–90. DOI: 10.1245/s10434–013–3090–7.
28. van Broekhoven DL, Verhoef C, Elias SG, Witkamp AJ, van Gorp JM, van Geel BA, et al. Local recurrence after surgery for primary extra-abdominal desmoid-type fibromatosis. Br J Surg. 2013 Aug;100 (9):1214–9. DOI: 10.1002/bjs.9194.
29. Harati K, Jaenisch A, Behr B, Goertz O, Harati A, Hirsch T, et al. Effect of surgical margins on prognosis in aggressive fibromatosis: A single-institutional analysis of 90 patients. Oncol Lett. 2017 Nov;14 (5):5129–5134. DOI: 10.3892/ol.2017.6864
30. Wirth L, Klein A, Baur-Melnyk A, Knösel T, Lindner LH, Roeder F, et al. Desmoid Tumours of the extremity and trunk. A retrospective study of 44 patients. BMC Musculoskelet Disord. 2018 Jan 5;19 (1):2. doi: 10.1186/s12891–017–1924–3.
31. Peng PD, Hyder O, Mavros MN, Turley R, Groeschl R, Firoozmand A, et al. Management and Recurrence Patterns of Desmoids Tumors: A Multi-institutional Analysis of 211 Patients. Ann Surg Oncol. 2012 Dec;19 (13):4036–42. DOI: 10.1245/s10434–012–2634–6
32. Shido Y, Nishida Y, Nakashima H, Katagiri H, Sugiura H, Yamada Y, Ishiguro N. Surgical treatment for local control of extremity and trunk desmoid tumors. Arch Orthop Trauma Surg. 2009 Jul;129 (7):929–33. DOI: 10.1007/s00402–008–0750–3.
Review
For citations:
Yadrina A.V., Karpenko V.Yu., Novikova O.V., Bychkova N.M., Derzhavin V.A., Bucharov A.V. PROGNOSTIC FACTORS OF RELAPSE IN THE SURGICAL TREATMENT OF DESMOID FIBROIDS OF THE TRUNK AND EXTREMITIES. Research and Practical Medicine Journal. 2019;6(1):21-32. (In Russ.) https://doi.org/10.17709/2409-2231-2019-6-1-2
Views:
1595
Email this article 